Efficacy and safety of bevacizumab-combined single-agent chemotherapy for platinum-resistant ovarian cancer that recurred during PARP inhibitor treatment
{{output}}
Background: Currently, there are no reports on the subsequent treatment of patients with ovarian cancer who exhibited platinum-resistant recurrence during treatment with poly (ADP-ribose) polymerase (PARP) inhibitors. This retros... ...
